CMS has successfully advised longstanding client Takeda Pharmaceutical Company Limited, the largest Japanese pharmaceutical company, on its € 9.6 billion (debt-free cash free) acquisition of European drug company Nycomed A/S. The deal is subject to competition clearances and so is expected to complete within 90 to 120 days.
This is one of the most significant deals to occur in the lifesciences sector this year and this acquisition notably increases Takeda’s footprint and strength in the European market and emerging markets.
Nycomed, headquartered in Zurich, is a privately owned, global pharmaceutical company with a diversified product portfolio including both established prescription pharmaceutical products and over the counter (OTC) products. They employ 12,500 associates worldwide and have affiliates in more than 70 countries.
CMS UK Lifesciences corporate partner Sandra Rafferty led the transaction team with support from specialists across CMS in the field of lifesciences, IP, due diligence, competition, tax, environmental, employment and banking.
This complex transaction involved seamless coordination between CMS offices in 13 countries including Austria, Belgium, China, France, Germany, Italy, Netherlands, Poland, Russia, Spain, Switzerland, UK and Ukraine. CMS also worked closely with local lawyers in certain markets.
The Dutch team was led by partners Reinout Slot (corporate) and Willem Hoorneman (IP) and included Clair Wermers (corporate), Eduard Scheenstra (banking), Bart Essink (company commercial), Ellen Gielen (lifesciences), and Ewoud Swart (IP).
CMS has one of the world’s leading lifesciences practices and for the last two years, CMS have been the number #1 law firm across Europe for M&A deals in the Lifesciences sector, as ranked by Mergermarket.